USA flag logo/image

An Official Website of the United States Government

Field Optimization of Real-time PCR for the detection of Leishmania parasites

Award Information

Agency:
Department of Defense
Branch:
Office of the Secretary of Defense
Award ID:
76505
Program Year/Program:
2005 / SBIR
Agency Tracking Number:
O043-H07-3106
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
Spire Corporation
One Patriots Park Bedford, MA 01730-2396
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2005
Title: Field Optimization of Real-time PCR for the detection of Leishmania parasites
Agency / Branch: DOD / OSD
Contract: W81XWH-05-C-0100
Award Amount: $99,974.00
 

Abstract:

The proposed Phase I SBIR program will develop a rapid assay for characterizing blood samples from patients with suspected Leishmania infection. Leishmaniasis affects 12 million people worldwide with 400,000 new cases diagnosed annually. The spectrum of diseases caused by Leishmania spp. includes cutaneous, diffuse cutaneous, mucocutaneous and visceral leishmaniasis (VL [kala-azar,]). Current methods for detection are complex, costly, time consuming, lack specificity, and difficult to execute. The proposed single nucleotide polymorphism (SNP) signature assay will enable identification to be carried out in single assay that is highly specific, easy to perform, inexpensive, and field deployable. The assay is carried out in two stages. First, a genus-specific RT PCR is carried out targeting the Leishmania genus. For positive samples the SNP signature assay will be carried using the amplicon generated for species identification. The prototype assay will be used to test a series of genomic isolates (positive and negative) that will be requested from the Walter Reed Army Medical Center (WRAMC) as blind samples. From the outcome, preliminary sensitivity and specificity will be determined. During Phase II, the assay will be finalized in terms of probe design, kit configuration, and accessory equipment, and external validation studies will be carried out.

Principal Investigator:

James G. Moe
Senior Scientist
7812756000
jmoe@spirecorp.com

Business Contact:

Mark C. Little
CEO, Spire Biomedical, Inc.
7812756000
mlittle@spirecorp.com
Small Business Information at Submission:

SPIRE CORP.
One Patriots Park Bedford, MA 01730

EIN/Tax ID: 042457335
DUNS: N/A
Number of Employees:
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No